comparemela.com

Latest Breaking News On - Prnewswire akeso inc - Page 5 : comparemela.com

Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) for advanced NSCLC at ASCO 2022

HONG KONG, June 5, 2022 /PRNewswire/ Akeso, Inc. (9926.HK) ( Akeso ), a China-based biopharmaceutical company focusing on the development and.

Prnewswire akeso incAkeso inc

Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022

/PRNewswire/ Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative.

Sri lankaPrnewswire akeso incAkeso incMetastatic cervical

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

/PRNewswire/ Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative.

United statesPenpulimab akesoAmerican association for cancer researchPrnewswire akeso incAkeso incAmerican associationCancer researchAnnual meeting

Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC

/PRNewswire/ Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that.

China national medical products administrationPrnewswire akeso incAkeso incDrug evaluationNational medical products administration

Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC

/PRNewswire/ Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that.

China national medical products administrationPrnewswire akeso incAkeso incDrug evaluationNational medical products administration

vimarsana © 2020. All Rights Reserved.